Cargando…

Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis

Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis. Results from 2 randomized, double‐blind, vehicle‐controlled phase 3 studies showed that twice‐daily crisaborole in children and adults with mild to moderate atopic derma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Purohit, Vivek, Riley, Steve, Tan, Huaming, Ports, William C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Non Covid Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540423/ https://www.ncbi.nlm.nih.gov/pubmed/32433779 http://dx.doi.org/10.1002/jcph.1624

Ejemplares similares

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
por: Luger, Thomas A., et al.
Publicado: (2022)

Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area
por: SILVERBERG, Jonathan I., et al.
Publicado: (2020)

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
por: Callender, Valerie D., et al.
Publicado: (2019)

In Vitro Skin Retention of Crisaborole after Topical Application
por: Fantini, Adriana, et al.
Publicado: (2020)

Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning
por: Purohit, Vivek S., et al.
Publicado: (2018)

Crisaborole for atopic dermatitis
Publicado: (2019)

Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling
por: Posada, Maria M., et al.
Publicado: (2020)

Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)
por: Schlessinger, Joel, et al.
Publicado: (2020)

Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users
por: Schippers, Frank, et al.
Publicado: (2020)

Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection
por: Deng, Rong, et al.
Publicado: (2020)

A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam
por: VanLandingham, Kevan E., et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule‐1 (MAdCAM‐1), in Patients With Ulcerative Colitis or Crohn's Disease
por: Wang, Yi, et al.
Publicado: (2020)

Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients
por: Provenzano, Robert, et al.
Publicado: (2020)

An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants
por: Li, Jia, et al.
Publicado: (2020)

Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects
por: Tellone, Valeria, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 Study
por: Vanhoutte, Frédéric, et al.
Publicado: (2020)

Exploring the Relationship Between Morphine Concentration and Oversedation in Children After Cardiac Surgery
por: Valkenburg, Abraham J., et al.
Publicado: (2020)

Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
por: Ankrom, Wendy, et al.
Publicado: (2020)

Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation
por: Renaud, Lionel, et al.
Publicado: (2020)

Repigmentation in a patient with vitiligo on crisaborole 2% ointment
por: Tam, Idy, et al.
Publicado: (2021)

Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study
por: Zane, Lee T., et al.
Publicado: (2016)

Clinical efficacy evaluation of crisaborole ointment in the treatment of vulvar leukoplakia
por: Li, Lijun
Publicado: (2023)

Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis
por: Thom, Howard, et al.
Publicado: (2021)

Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
por: Fowler, Joseph, et al.
Publicado: (2023)

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib
por: Srinivas, Nithya, et al.
Publicado: (2020)

Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment
por: Schultze‐Mosgau, Marcus‐Hillert, et al.
Publicado: (2020)

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018)

Nonlinear regression
por: Seber, G. A. F. (George Arthur Frederick), 1938-
Publicado: (2003)

Estimation of endogenous intestinal losses of acid hydrolyzed ether extract in growing and finishing pigs using the linear regression method
por: Acosta, Jesus A, et al.
Publicado: (2021)

Prevalent migraine as a predictor of incident hypertension
por: Entonen, Anitta H, et al.
Publicado: (2022)

Crisaborole Loaded Nanoemulsion Based Chitosan Gel: Formulation, Physicochemical Characterization and Wound Healing Studies
por: Ansari, Mohd Nazam, et al.
Publicado: (2022)

Crisaborole Inhibits Itch and Pain by Preventing Neutrophil Infiltration in a Mouse Model of Atopic Dermatitis
por: PAVLENKO, Darya, et al.
Publicado: (2023)

Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
por: Laracy, Justin C., et al.
Publicado: (2023)

Nonlinear Regression with R
por: Ritz, Christian, et al.
Publicado: (2009)

Translating the Investigator’s Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis
por: Thyssen, Jacob P., et al.
Publicado: (2021)

A regression discontinuity analysis of the social distancing recommendations for older adults in Sweden during COVID-19
por: Bonander, Carl, et al.
Publicado: (2022)

Topics in nonlinear functional analysis
por: Nirenberg, Louis
Publicado: (2001)

Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Nonlinear regression analysis and its applications /
por: Bates, Douglas M.
Publicado: (1988)

Nonlinear regression analysis and its applications
por: Bates, Douglas M, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ic4uai8puvhd1jbf556pc100i1